


# Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve: The RIVER Trial

**Background:** The effects of rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve remain uncertain. RIVER trial was conducted to assess the efficacy and safety of rivaroxaban as compared with warfarin in patients with AF and a bioprosthetic mitral valve.



- Multicenter, open-label, randomized, noninferiority trial in Brazil
- Patients with AF and a bioprosthetic mitral valve were included



## Mean time until primary-outcome:



Rivaroxaban group	347.5 days
Warfarin group	340.1 days

P<0.001 for noninferiority

The primary outcome: Composite of death, major cardiovascular events or major bleeding at 12 months

## Major bleeding events:

Rivaroxaban group	7 patients (1.4%)
Warfarin group	13 patients (2.6%)

HR, 0.54; 95% CI, 0.21 to 1.35



In patients with atrial fibrillation and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin with respect to the mean time until the primary outcome of death, major cardiovascular events, or major bleeding at 12 months.